Tag: Gilead Sciences

Gilead and Sangamo joined up for development of next gen cell therapies

Kite, a Gilead Company, and Sangamo Therapeutics entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.

GSK brings legal action against Gilead Sciences

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Ltd., announced that it has filed patent infringement litigation against Gilead Sciences

Gilead starts a new clinical collaboration with Pfizer

Kite, a Gilead Company, announced a clinical trial collaboration with Pfizer to evaluate the safety and efficacy of the investigational combination of Yescarta and Pfizer's utomilumab

Gilead Sciences buys Cell Design Labs

Gilead Sciences and its subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs

Gilead Sciences completed the purchase of Kite Pharma

Gilead Sciences, Inc. announced the completion of the previously announced transaction for a subsidiary of Gilead to acquire Kite Pharma

Gilead Sciences will pay $11.9 million for Kite Pharma

Gilead Sciences, Inc. and Kite Pharma, Inc. announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash